Otsuka Pharmaceutical
Otsuka Pharmaceutical Co. Ltd. is a brand.
Last updated October 7, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Otsuka Pharmaceutical Co., Ltd. is a Japanese multinational healthcare company headquartered in Chiyoda-ku, Tokyo. Established on August 10, 1964, it operates as a wholly owned subsidiary of Otsuka Holdings and serves as one of the central operating companies in the broader Otsuka Group. The company develops, manufactures, markets, exports, and imports prescription pharmaceuticals, diagnostic and clinical-testing products, medical devices, food products, cosmetics, and related health products. The company’s identity is built around a combination of medical innovation and everyday health maintenance. Its pharmaceutical business emphasizes research-driven medicines for areas where Otsuka believes substantial unmet needs remain, particularly central nervous system disorders, neurology, oncology, cardiovascular and renal diseases, tuberculosis, ophthalmology, gastroenterology, infectious diseases, and dermatology. Its nutraceutical business develops products intended to support hydration, nutrition, physical performance, metabolic health, supplementation, and daily well-being. This dual structure distinguishes Otsuka from companies focused exclusively on prescription drugs and allows it to operate across hospitals, pharmacies, clinical settings, supermarkets, convenience stores, vending channels, sports venues, and direct consumer markets. Otsuka’s best-known consumer products include Pocari Sweat, a hydration beverage positioned around fluid and electrolyte replenishment; CalorieMate, a compact nutritional food; Oronamin C Drink, a vitamin beverage; SOYJOY, a soy-based snack; Amino-Value; and Nature Made vitamins and supplements, which entered the Otsuka portfolio through the acquisition of Pharmavite. The company also markets functional foods, dietary supplements, cosmetics, and other consumer-health products in Japan and internationally. Product availability varies by market, and many locally important brands are sold through Otsuka subsidiaries or regional operating companies. In prescription medicines, Otsuka is associated internationally with aripiprazole, marketed in major markets as Abilify through arrangements involving Otsuka and commercial partners; brexpiprazole, marketed as Rexulti; and a broader portfolio of psychiatric, neurological, oncology, renal, infectious-disease, and specialty medicines. The company’s research culture is deliberately oriented toward unconventional approaches and underserved conditions. Otsuka states that its first drug-discovery research institute opened in 1971 and that its research network now spans Asia, the United States, and Europe. Otsuka has expanded through a mixture of internal discovery, licensing, partnerships, and acquisitions. Its portfolio has included Pharmavite, the California-based maker of Nature Made and other nutritional brands; Astex Pharmaceuticals; Avanir Pharmaceuticals; Neurovance; Visterra; Mindset Pharma; Jnana Therapeutics; and other businesses or programs connected with specialty pharmaceuticals and biotechnology. The company has also maintained interests beyond core medicines, including nutrition, food, medical devices, and selected beverage and wellness activities. Some businesses associated with the wider Otsuka Group, such as Otsuka Pharmaceutical Factory, Taiho Pharmaceutical, Otsuka Foods, Otsuka Medical Devices, and Otsuka Chemical, are separate operating companies rather than divisions of Otsuka Pharmaceutical itself. Otsuka Pharmaceutical is not itself a separately listed public company. Its parent, Otsuka Holdings, completed an initial public offering on the Tokyo Stock Exchange in December 2010. Under President and Representative Director Makoto Inoue, Otsuka Pharmaceutical continues to present itself as a total-healthcare company whose medical and nutraceutical businesses are linked by the corporate philosophy “Otsuka-people creating new products for better health worldwide.”
History
Otsuka Pharmaceutical’s corporate history is part of the longer development of the Otsuka Group, whose origins are associated with Busaburo Otsuka and a business established in Tokushima in the early twentieth century. The group’s original pharmaceutical and clinical-nutrition activities later developed into several operating companies. Otsuka Pharmaceutical Co., Ltd. was formally established on August 10, 1964, and became the group’s principal company for prescription pharmaceuticals and nutraceutical products. A defining feature of Otsuka’s development was the decision to combine drug discovery with products intended for everyday health. Rather than treating food and beverages as unrelated consumer businesses, the company positioned its nutraceutical activities as scientifically grounded products addressing hydration, nutrition, supplementation, physical activity, and preventive health. This approach produced brands such as Pocari Sweat, CalorieMate, Oronamin C Drink, Amino-Value, and SOYJOY. These products became particularly important in Japan, where Otsuka developed distinctive categories instead of competing only within established soft-drink or snack segments. Otsuka also built a research-centered pharmaceutical business. Its first drug-discovery research institute opened in 1971. Over subsequent decades, the company developed and commercialized medicines in psychiatry, neurology, oncology, cardiovascular and renal medicine, infectious disease, gastroenterology, ophthalmology, and other specialty areas. Psychiatric and neurological medicines became especially associated with the company’s international profile, including aripiprazole and brexpiprazole. Otsuka’s stated research philosophy emphasizes pursuing scientific approaches that may be overlooked by larger competitors and addressing diseases with significant unmet medical needs. International expansion accelerated through acquisitions and regional subsidiaries. In 1988, Otsuka acquired Pharmavite in the United States, bringing the Nature Made supplement brand and a substantial North American nutrition platform into the group. The company subsequently developed a broader international footprint through Otsuka America Pharmaceutical, Otsuka Pharmaceutical Europe, Pharmavite, Nardobel, and other affiliates. In 2008, Otsuka acquired a minority stake in Alma S.A., the parent company of CG Roxane, reflecting the group’s willingness to operate beyond prescription medicines and conventional nutraceuticals. Otsuka’s portfolio-building strategy became more visible in the 2010s. The parent company, Otsuka Holdings, listed on the Tokyo Stock Exchange in December 2010. In early 2012, Otsuka announced that its future operations would concentrate more heavily on central nervous system disorders and oncology. The shift led to changes in the company’s collaboration arrangements with UCB, including the ending of certain immunology collaborations while retaining work in the central nervous system field. The decision clarified Otsuka’s strategic priorities at a time when the company was increasingly building an international specialty-pharmaceutical portfolio. The company pursued a series of acquisitions to support those priorities. Otsuka acquired Astex Pharmaceuticals in 2013, strengthening oncology discovery and development. In 2014 it acquired Avanir Pharmaceuticals, adding neurological products and expertise. In 2017 it agreed to acquire Neurovance and the investigational ADHD compound centanafadine. Otsuka also acquired or integrated businesses and technologies connected with medical devices, biotechnology, antibody engineering, and plant-based nutrition, including Visterra, Daiya, and ReCor Medical. These transactions broadened the group while maintaining a strong emphasis on specialty healthcare. During the 2020s, Otsuka continued to use acquisitions to supplement internal research. The company announced the acquisition of Mindset Pharma in 2023 and completed its acquisition of Jnana Therapeutics in 2024. These deals reflected interest in new drug-discovery technologies and central nervous system or metabolic disease programs. In 2026, Otsuka announced and then completed the acquisition of Transcend Therapeutics through Otsuka America. Transcend brought TSND-201, an investigational rapid-acting neuropsychiatric treatment being studied for post-traumatic stress disorder, into Otsuka’s development portfolio. Today, Otsuka Pharmaceutical operates as a wholly owned subsidiary of Otsuka Holdings. Its business description covers research, development, manufacture, sale, export, and import of pharmaceuticals, clinical-testing equipment, medical devices, food products, cosmetics, and related goods. The company’s current structure reflects a long-running strategy: combine pharmaceutical innovation in difficult or underserved therapeutic areas with consumer-facing nutrition and wellness products that can create new markets. Its corporate philosophy, “Otsuka-people creating new products for better health worldwide,” summarizes this integrated healthcare positioning.
- 2026
Transcend Therapeutics acquired
[7]Otsuka agreed to acquire and subsequently completed the acquisition of Transcend Therapeutics, adding the investigational PTSD candidate TSND-201.
- 2024
Jnana Therapeutics acquisition completed
[5]Otsuka completed its acquisition of Jnana Therapeutics and added its drug-discovery platform and development programs.
- 2023
Mindset Pharma acquisition announced
[6]Otsuka announced the acquisition of Mindset Pharma to strengthen its central nervous system discovery capabilities.
- 2018
Visterra acquisition agreed
[6]Otsuka agreed to acquire Visterra, adding antibody-engineering technology and biologic development capabilities.
- 2017
Neurovance acquisition agreed
[6]Otsuka agreed to acquire Neurovance and its investigational ADHD candidate centanafadine.
- 2014
Avanir Pharmaceuticals acquired
[6]The acquisition strengthened Otsuka’s presence in neurological and specialty medicines.
- 2013
Astex Pharmaceuticals acquired
[6]Otsuka acquired Astex Pharmaceuticals, expanding its oncology capabilities and small-molecule discovery platform.
- 2012
Strategic focus shifts toward CNS and oncology
[6]Otsuka announced a stronger future emphasis on central nervous system disorders and oncology, leading to revisions in some collaboration arrangements.
- 2010
Otsuka Holdings IPO
[6]Otsuka Holdings completed its initial public offering on the Tokyo Stock Exchange. Otsuka Pharmaceutical remained a wholly owned operating subsidiary.
- 2008
Minority investment in Alma S.A.
[6]Otsuka acquired a 49 percent stake in Alma S.A., the parent company of CG Roxane.
Products and positioning
Science-led total healthcare company spanning prescription medicines, specialty therapeutics, nutraceuticals, functional foods, hydration, diagnostics, and medical devices.
Hydration beverage
Pocari Sweat
Pocari Sweat is Otsuka’s flagship hydration beverage and one of its most internationally recognizable consumer brands. It is positioned as a scientifically formulated drink for replenishing water and electrolytes lost through sweating, exercise, heat, or illness. The brand is marketed through sports, health, and everyday hydration contexts rather than solely as a conventional soft drink. Product formulations and packaging vary by country, while the core positioning centers on hydration and physiological fluid balance.
Functional food
CalorieMate
CalorieMate is a compact nutritional food sold primarily in bar, block, jelly, and drink formats. Otsuka positions it as a convenient source of balanced nutrition for people with demanding schedules, study routines, travel needs, or limited meal time. The product has developed into a distinct Japanese functional-food category and is marketed around portability, predictable nutritional content, and ease of consumption rather than indulgent snacking.
Functional beverage
Oronamin C Drink
Oronamin C Drink is a Japanese vitamin-oriented carbonated beverage. It combines a soft-drink format with messaging around vitamin C and refreshment, giving Otsuka a consumer product positioned between mainstream beverages and functional nutrition. The brand has long been associated with energetic advertising and broad everyday consumption in Japan. It is separate from Otsuka’s prescription pharmaceutical portfolio but reflects the company’s strategy of creating science- or health-associated consumer categories.
Vitamins and dietary supplements
Nature Made
Nature Made is a major vitamin and dietary-supplement brand owned and operated through Pharmavite, an Otsuka company. The line includes vitamins, minerals, specialty supplements, and other nutritional products sold primarily in North America and selected international markets. Its positioning emphasizes accessible supplementation, standardized products, and everyday health maintenance. The brand materially expanded Otsuka’s consumer-health presence in the United States after the Pharmavite acquisition.
Soy-based nutritional snack
SOYJOY
SOYJOY is a soy-based snack bar designed to provide a portable food option with protein and other nutritional components. Otsuka markets the brand as an alternative to conventional snack bars, with an emphasis on soy, convenience, and controlled portioning. It belongs to the company’s nutraceutical and functional-food portfolio and is sold in multiple flavors and market-specific formats.
Functional beverage and amino-acid nutrition
Amino-Value
Amino-Value is a functional nutrition line built around amino-acid supplementation and hydration-related consumer needs. It is associated with sports, physical activity, and recovery-oriented use cases. The product illustrates Otsuka’s practice of combining beverage convenience with a targeted nutritional proposition rather than competing solely on taste or refreshment. Availability and exact product configuration differ by market.
Prescription medicine
Abilify
Abilify is the international brand name associated with aripiprazole, an atypical antipsychotic developed by Otsuka and commercialized in various markets through partnerships and regional arrangements. It became one of Otsuka’s most important global pharmaceutical products and helped establish the company’s international reputation in psychiatry. Approved uses, labeling, formulations, and commercialization rights vary by jurisdiction, and some markets use generic aripiprazole after patent or exclusivity periods.
Prescription medicine
Rexulti
Rexulti is the brand name for brexpiprazole, a prescription medicine developed within Otsuka’s central nervous system portfolio. It is associated with psychiatric indications and has been commercialized internationally through Otsuka and partners. The product reflects the company’s long-term concentration on neuroscience, especially medicines that address serious mental-health conditions and related treatment gaps.
Investigational neuropsychiatric medicine
TSND-201
TSND-201 is an investigational compound acquired through Otsuka’s purchase of Transcend Therapeutics. It is being developed as a rapid-acting neuroplastogen for post-traumatic stress disorder and potentially other psychiatric conditions. Otsuka describes the program as part of its effort to expand next-generation psychiatric treatments. TSND-201 remains a development-stage candidate and is not an approved commercial product.
Marketing campaigns
- 1955Otsuka Pharmaceutical SC football program
Japan
Otsuka established a football club, Otsuka Pharmaceutical SC, creating a long-running connection between the company and regional sports culture in Tokushima.
Outcome. The club was renamed Tokushima Vortis in 2005 and continued as a professional football organization.
- Pocari Sweat sports and hydration marketing
Japan · Asia-Pacific · Middle East · Other international markets
Pocari Sweat has been marketed through sports, exercise, heat, and hydration contexts, linking the beverage with athletic performance and daily fluid replenishment. The approach supports Otsuka’s broader strategy of presenting nutraceutical products as scientifically grounded health products rather than ordinary soft drinks.
Outcome. The campaign platform helped make Pocari Sweat one of Otsuka’s most recognizable consumer brands, although a single global campaign end date is not established in the available sources.
Brand decisions
2026
Acquisition of Transcend TherapeuticsM&ABackground
Transcend Therapeutics was developing TSND-201, an investigational rapid-acting neuroplastogen for post-traumatic stress disorder and other neuropsychiatric conditions.
Action taken
Otsuka America agreed to acquire all outstanding shares of Transcend and completed the transaction in June 2026, making Transcend a wholly owned subsidiary.
Aftermath
The acquisition expanded Otsuka’s psychiatric and neurological pipeline and gave the company control of TSND-201’s further development.
Acquisition consideration. USD 700 million at completion, with potential contingent consideration of up to USD 525 million based on future sales (Agreement announced March 27, 2026; acquisition completed June 15, 2026)
2024
Acquisition of Jnana TherapeuticsM&ABackground
Otsuka sought to acquire new drug-discovery technology and a pipeline with potential applications in metabolic and other diseases.
Action taken
Otsuka completed the acquisition of Jnana Therapeutics and brought its discovery platform and development programs into the group.
Aftermath
The deal strengthened Otsuka’s external innovation strategy and added a potential oral treatment program for phenylketonuria.
2023
Acquisition of Mindset PharmaM&ABackground
Otsuka continued expanding its central nervous system discovery capabilities and sought external technologies relevant to psychiatric drug research.
Action taken
Otsuka announced an agreement to acquire Mindset Pharma.
Aftermath
The transaction added Mindset’s research capabilities to Otsuka’s broader neuroscience strategy.
Announced acquisition value. USD 58.6 million (Announced in late 2023)
2017
Acquisition of NeurovanceM&ABackground
Neurovance owned centanafadine, an investigational ADHD compound considered sufficiently advanced to support further clinical development.
Action taken
Otsuka agreed to acquire Neurovance through Otsuka America. The announced structure included USD 100 million upfront and up to USD 150 million in development and approval milestones.
Aftermath
Neurovance became an indirect wholly owned subsidiary, adding another neuroscience development program to Otsuka’s portfolio.
Acquisition consideration. USD 100 million upfront plus up to USD 150 million in development and approval milestones (Announced March 2017)
2013
Acquisition of Astex PharmaceuticalsM&ABackground
Otsuka sought to strengthen its oncology pipeline and small-molecule discovery capabilities.
Action taken
Otsuka acquired Astex Pharmaceuticals and integrated its oncology research and development capabilities into the wider group.
Aftermath
The transaction expanded Otsuka’s presence in oncology and supported its strategy of supplementing internal research with external innovation.
2012
Concentration on central nervous system disorders and oncologyStrategyBackground
Otsuka reviewed its future pharmaceutical priorities and identified central nervous system disorders and oncology as key areas for concentration.
Action taken
The company revised certain collaboration arrangements, including ending collaboration on some immunology products with UCB while continuing cooperation in the central nervous system field.
Aftermath
The decision reinforced Otsuka’s long-term identity as a specialty pharmaceutical company with particular strength in psychiatry, neurology, and oncology.
Recent events
Aurinia and Otsuka announce voclosporin collaboration and licensing agreement[11]
Reported:
Aurinia announced a collaboration and license agreement with Otsuka for the development and commercialization of oral voclosporin for lupus nephritis in the European Union, Japan, the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.
Court approves Otsuka’s bid to acquire Proteus[12]
Reported:
A Delaware bankruptcy court approved Otsuka Pharmaceutical’s bid to acquire Proteus for $15 million in cash. The approval allows Otsuka to integrate Proteus’ business with its own; the article does not report that the acquisition has been completed.
Responsum Health launches Responsum for CKD[13]
Reported:
Responsum Health, with support from Otsuka Pharmaceutical, announced the launch of Responsum for CKD, a free online and mobile platform for people with kidney disease. It provides curated health news, a moderated community space, patient information tools, and support links.
Sources14 sources
- 1Otsuka Pharmaceutical Corporate Profileotsuka.co.jp
- 2Otsuka Pharmaceutical Main Operating Company Profileotsuka.com
- 3Otsuka Pharmaceutical Business Overviewotsuka.co.jp
- 4Otsuka Holdings Board Membersotsuka.com
- 5Otsuka Holdings 2025 Annual Reportotsuka.com
- 6Otsuka Pharmaceutical Wikipedia articleen.wikipedia.org
- 7Otsuka Pharmaceutical Completes Acquisition of Transcend Therapeuticsotsuka.co.jp
- 8Otsuka Pharmaceutical Announces Acquisition of Transcend Therapeuticsotsuka.co.jp
- 9Origins of the Otsuka Groupotsuka.com
- 10Pocari Sweat sports and hydration marketingotsuka.co.jp
- 11Aurinia与大冢宣布voclosporin合作及许可协议finanznachrichten.de
- 12法院批准Otsuka收购Proteus的竞标medcitynews.com
- 13Responsum Health推出Responsum for CKDprweb.com
- 14Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japaninvestingnews.com
Cite this profile: Cite the canonical profile. /brand-wiki/otsuka-pharmaceutical · Editorial policy · How profiles are compiled